Bioxytran, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 4.28 million compared to USD 2.46 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.02 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.12 USD | -11.11% | -9.43% | -20.00% |
Apr. 19 | Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 22 | Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-20.00% | 21M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- BIXT Stock
- News Bioxytran, Inc.
- Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023